What's New in CLL Post ASCO 2019: BCL-2 Inhibitors
Avatar

Combining Novel Agents in Chronic Lymphocytic Leukemia: Greater Than the Sum of its Parts?

By What's New in CLL Post ASCO 2019: BCL-2 Inhibitors FEATURING Arnon Kater
By What's New in CLL Post ASCO 2019: BCL-2 Inhibitors FEATURING Arnon Kater
275 views
August 21, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

06:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…

Feat. M. Shadman
10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
15:21
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
06:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…

Feat. A. Kittai
08:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of CLL - Highlights & Key Takea…

Feat. V. Yazbeck
06:28
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…

Feat. O. Al-Sawaf
06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
11:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…

Feat. G. Gaidano
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
05:12
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With …

Feat. N. Shah
13:16
ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

Feat. S. O'Brien, C. Coombs
10:19
Alvaro Alencar

Pirtobrutinib in R/R CLL

10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CLL

Feat. N. Jain
28:43
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Scripps MD Anderson Cancer Center Updates on CLL/SLL Frontline Thera…

Feat. S. O'Brien
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…